Insulet (PODD) Cash from Investing Activities (2010 - 2026)
Insulet (PODD) posted Cash from Investing Activities of -$27.7 million for Q1 2026, up 81.87% on a QoQ basis from -$152.8 million in Q4 2025, and down 77.56% year-over-year from -$123.5 million in Q1 2025.
Insulet (PODD) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Insulet's Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$27.7 million for Q1 2026.
- Quarterly Cash from Investing Activities fell 77.56% year-over-year to -$27.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$234.8 million (down 70.39% YoY) and the FY2025 annual result came in at -$222.7 million, down 52.33% from the prior year.
- Cash from Investing Activities was -$27.7 million for Q1 2026 at Insulet, up from -$152.8 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$15.6 million in Q1 2025 and bottomed at -$152.8 million in Q4 2025.
- A 5-year average of -$41.6 million and a median of -$29.3 million in 2024 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities sank 177.87% — and 2023, when it soared 64.25%.
- Insulet's Cash from Investing Activities stood at -$88.4 million in 2022, then surged by 64.25% to -$31.6 million in 2023, then tumbled by 115.19% to -$68.0 million in 2024, then plunged by 124.71% to -$152.8 million in 2025, then surged by 81.87% to -$27.7 million in 2026.
- Business Quant data shows PODD's Cash from Investing Activities at -$27.7 million in Q1 2026, -$152.8 million in Q4 2025, and -$31.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -92.80 Mn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | -298.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -2.50 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | -475.32 Mn |
| 10 | Insulet | 11.52 Bn | 11.04 Bn | 529.10 Mn | -27.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.70 Mn |
| Mar 31, 2026 | -27.70 Mn |
| Dec 31, 2025 | -152.80 Mn |
| Dec 31, 2025 | -152.80 Mn |
| Sep 30, 2025 | -31.00 Mn |
| Sep 30, 2025 | -31.00 Mn |
| Jun 30, 2025 | -23.30 Mn |
| Jun 30, 2025 | -23.30 Mn |
| Mar 31, 2025 | -15.60 Mn |
| Mar 31, 2025 | -15.60 Mn |
| Dec 31, 2024 | -68.00 Mn |
| Dec 31, 2024 | -68.00 Mn |
| Sep 30, 2024 | -29.30 Mn |
| Sep 30, 2024 | -29.30 Mn |
| Jun 30, 2024 | -24.90 Mn |
| Jun 30, 2024 | -24.90 Mn |
| Mar 31, 2024 | -24.00 Mn |
| Mar 31, 2024 | -24.00 Mn |
| Dec 31, 2023 | -31.60 Mn |
| Dec 31, 2023 | -31.60 Mn |